Figure 6. Retrograde labeling of the corticopontine cells revealed layer 5-restricted elaboration of the dendritic processes.
Image credit: Watakabe, et. al. 2012 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Preclinical Research in Rare Diseases, Translational Steps in Large Animals
Sponsor: French Foundation for Rare Diseases
Description: Translational research represents a link between exploratory steps of proofs of principle to clinical application in humans. In some cases, the use of larger animal models is necessary to confirm the relevance of a concept or to demonstrate the feasibility, the efficiency and the safety of a therapeutic approach in conditions that mimic as closely as possible the human situation. This call aims to directly support intermediary key steps towards clinical development for patients using these models in France. Animals in the scope of this call are usually pigs, sheep, dogs and nonhuman primates. Up to 100,000€ will be awarded.
Deadline: Application due by October 24, 2017.



NEW! Dynamic Neuroimmune Interactions in the Transition from Normal CNS Function to Disorders
Sponsor: NIH Blueprint for Neuroscience Research
Description: The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). The goal of this FOA, which is an R01, is to transform our understanding of how dynamic interactions among multiple cell types involved in neuroimmune interactions (e.g., neurons, glia cells, neurovascular units, or other neuroimmune components) mediate the transition from normal central nervous system (CNS) function to disorder conditions. The budgets are limited to $400,000 direct costs annually for at most 5 years.
Deadline: Letter of Intent due by November 7, 2017.



NEW! ALS Accelerated Therapeutics (ALS ACT)
Sponsor: ALS Finding a Cure, ALS Association and NEALS
Description: This program funds phase I/II clinical trial applications for novel, high-potential treatments in ALS. The call is intended for academic-industry partnerships, including pharmaceutical, biotherapeutic/biotechnology companies, academic members of NEALS, and ALS scientists throughout the world. Up to USD $1,500,000 in ALS ACT clinical research support is available - including up to 10% indirect costs. Industry partnership applications are strongly encouraged with shared funding proposals.
Deadline: Letter of Intent due by November 10, 2017.



NEW! Technological Innovations in Neuroscience Awards
Sponsor: The McKnight Foundation
Description: This program seeks to advance and enlarge the range of technologies available to the neurosciences. These awards support scientists working on new and unusual approaches to understanding brain function. Technology may take any form, from biochemical tools to instruments to software and mathematical approaches. The fund is especially interested in how the technology may be used or adapted to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Awards provide up to $100,000 per year for two years. Research based primarily on existing techniques will not be considered.
Deadline: Letter of Intent due by December 4, 2017.



NEW! Rapid Response: Canada 2018
Sponsor: Weston Brain Institute
Description: This program provides seed funding for high-risk, high-reward, translational research projects on neurodegenerative diseases of aging including FTD.   A maximum of $200,000 over up to 18 months per project. Principal applicants must be researchers working in Canada at least 30% of the time above the level of Postdoctoral Fellow, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Letters of Intent will begin to be accepted in November 2017.
Deadline: Application due by January 2018.



NEW! Altman Award in Developmental Neuroscience (Worldwide)
Sponsor: Japan Neuroscience Society
Description: This award focuses on developmental neuroscience at the cellular and/or tissue level. Projects recognized include adult neurogenesis and its biological significance and its changes resulting from aging and diseases. The award is $10,000 USD. Researchers worldwide are invited to apply. Applicants must hold a PhD for no more than 20 years. Applications accepted beginning November 1, 2017.
Deadline: Application due by January 31, 2018.



NEW! Rapid Response: Europe 2018
Sponsor: Weston Brain Institute
Description: Provides seed funding up to £175,000 per project for over up to 2 years for novel, high-risk, high-reward translational research projects that accelerate the development of therapeutics for neurodegenerative diseases of aging including FTD based in Europe. Applications will begin to be accepted in December 2017.
Deadline: Application due by March 2018.



NEW! Identify, Analyze and Evaluate Potential Risk Factors for ALS
Sponsor: CDC
Description: The purpose of this funding opportunity announcement (FOA) is to allow for investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the National ALS Registry's mission. Maximum award is $400,000 USD. Note: This is a forecasted opportunity.
Deadline: February 16, 2018 (estimated).



Biomedical Research Project Grants
Sponsor: Motor Neurone Disease Association
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Applications for project grants should not exceed £85,000 per annum (and £255,000 in total) without the prior agreement of the MND Association.
Deadline: Application due by November 3, 2017.



MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by December 1, 2017.



NeuroNEXT Clinical Trials
Sponsor: NINDS
Description: This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.
Deadline: Application due by December 6, 2017.



Transformational Research: Canada 2018
Sponsor: Weston Brain Institute
Description: This program funds transformative, novel, high-risk, high-reward translational research projects with excellent preliminary data aimed at accelerating the development of therapies for neurodegenerative diseases of aging including FTD. A maximum of $1,500,000 over up to 3 years per project. PIs must be at or above the level of Assistant Professor or equivalent, work in Canada at least 30% of the time, and be affiliated with a CRA-qualified institution.
Deadline: Letter of Intent due by December 7, 2017.



High Impact Neuroscience Research Resource Grants
Sponsor: NINDS
Description: This funding opportunity announcement (FOA) supports high impact efforts to make resources available to neuroscience researchers. Projects should engage in one or more of the following activities: facilitating access to cutting edge reagents or techniques, dissemination of resources to new user groups, or innovative approaches to increase the scale/efficiency of resource production and delivery. Applications focused primarily on technology or software development are not responsive to this FOA, as the focus is on dissemination or provision of resources. Use of existing technologies to develop new reagents or genetic lines of significant value to the research community may be appropriate. Projects should address compelling needs of broad communities of neuroscience researchers or should offer unique services that otherwise would be unavailable.
Deadline: Application due by February 9, 2018.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail